Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
December 11, 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a...
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
December 04, 2024 16:56 ET
|
Jupiter Neurosciences, Inc.
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
December 02, 2024 19:00 ET
|
Jupiter Neurosciences, Inc.
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...
GT Biopharma Reports Third Quarter 2024 Financial Results
November 14, 2024 16:00 ET
|
GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in...
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
November 13, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
November 05, 2024 07:10 ET
|
BioRestorative Therapies, Inc
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative...
Interim results for the six months ended June 30, 2024
September 26, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an...
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
September 24, 2024 09:15 ET
|
GT Biopharma, Inc.
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
September 19, 2024 06:55 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
September 04, 2024 09:25 ET
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...